Department of Molecular Biology, Genentech Inc., South San Francisco, CA 94080, USA.
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19368-73. doi: 10.1073/pnas.1204384109. Epub 2012 Nov 7.
The protein kinase v-akt murine thymoma viral oncogene homolog (AKT), a key regulator of cell survival and proliferation, is frequently hyperactivated in human cancers. Intramolecular pleckstrin homology (PH) domain-kinase domain (KD) interactions are important in maintaining AKT in an inactive state. AKT activation proceeds after a conformational change that dislodges the PH from the KD. To understand these autoinhibitory interactions, we generated mutations at the PH-KD interface and found that most of them lead to constitutive activation of AKT. Such mutations are likely another mechanism by which activation may occur in human cancers and other diseases. In support of this likelihood, we found somatic mutations in AKT1 at the PH-KD interface that have not been previously described in human cancers. Furthermore, we show that the AKT1 somatic mutants are constitutively active, leading to oncogenic signaling. Additionally, our studies show that the AKT1 mutants are not effectively inhibited by allosteric AKT inhibitors, consistent with the requirement for an intact PH-KD interface for allosteric inhibition. These results have important implications for therapeutic intervention in patients with AKT mutations at the PH-KD interface.
蛋白激酶 v-akt 鼠胸腺瘤病毒癌基因同源物(AKT)是细胞存活和增殖的关键调节因子,在人类癌症中经常过度激活。分子内的pleckstrin 同源(PH)结构域-激酶结构域(KD)相互作用对于维持 AKT 的非活性状态很重要。AKT 的激活是在构象变化后发生的,这种构象变化会使 PH 从 KD 上脱离。为了了解这些自动抑制相互作用,我们在 PH-KD 界面处产生突变,发现大多数突变导致 AKT 的组成性激活。这种突变可能是 AKT 在人类癌症和其他疾病中激活的另一种机制。为了支持这种可能性,我们在 PH-KD 界面处发现了 AKT1 的体细胞突变,这些突变以前在人类癌症中没有被描述过。此外,我们还表明 AKT1 体细胞突变是组成性激活的,导致致癌信号。此外,我们的研究表明,所有构象 AKT 抑制剂都不能有效地抑制 AKT1 突变体,这与完整的 PH-KD 界面对于所有构象抑制的要求一致。这些结果对于 AKT 突变体在 PH-KD 界面处的患者的治疗干预具有重要意义。